Section
The integrated 40-gene expression profile (i40-GEP) improves risk stratification in high-risk cutaneous squamous cell carcinoma, accurately predicting metastasis and local recurrence, and identifying patients who benefit most from adjuvant
This study demonstrates that tildrakizumab, an IL-23 inhibitor, partially reverses accelerated epigenetic aging in psoriasis patients, highlighting a novel aspect of biologic therapy beyond skin inflammation control.
This review examines emerging evidence on AI-assisted LC-OCT as a noninvasive, accurate tool for detecting subclinical basal cell carcinoma in high-risk patients, highlighting diagnostic performance, subtype classification, and translationa
Emerging evidence from prospective birth cohorts reveals a dose-dependent association between early respiratory infections and the risk of childhood atopic dermatitis, independent of genetic predisposition and antibiotic exposure.
This exploratory study suggests oral dapsone benefits refractory rosacea patients, highlighting a ‘high inflammatory burden’ subtype that may predict treatment response, offering a framework for precision dermatologic care.
Two large phase 3 trials demonstrated that upadacitinib significantly improves hair regrowth and quality of life in severe alopecia areata among adolescents and adults, with a consistent and manageable safety profile.
Blood or marrow transplant recipients face an increased risk of skin cancers. This study develops validated risk models to identify high-risk patients for basal cell carcinoma, squamous cell carcinoma, and melanoma to optimize surveillance
This review synthesizes current evidence on upadacitinib for alopecia areata, focusing on long-term efficacy, safety, and predictors of treatment response, highlighting the real-world retrospective study by Wang et al. alongside emerging cl
This study details the early-onset vocal symptoms and cutaneous features of lipoid proteinosis, highlighting significant, sustained voice improvements after microlaryngosurgery and supporting early surgical intervention for optimizing patie
Updated PIVOTAL Phase III trial data demonstrate that neoadjuvant intralesional Daromun significantly improves recurrence-free and distant metastasis-free survival in resectable stage III melanoma without new safety concerns at 36.8 months
The COMBI-I trial demonstrates that adding spartalizumab to dabrafenib and trametinib improves overall survival in patients with BRAF V600-mutant advanced melanoma after over 6 years of follow-up, despite not meeting the initial progression
An expert Delphi panel established a standardized, descriptive classification for pyoderma gangrenosum (PG) to improve diagnosis, research, and treatment planning by defining distinct phenotypes and key disease modifiers.
Reflectance confocal microscopy features at week 4 post-dupilumab treatment, combined with deep learning analysis, enable non-invasive prediction of therapeutic response in facial atopic dermatitis patients.
This review synthesizes current evidence on adalimumab, secukinumab, and bimekizumab for moderate-to-severe hidradenitis suppurativa, emphasizing clinical efficacy, safety, mechanistic insights, and cost-effectiveness across diverse health
Longitudinal monitoring reveals that persistence and growth dynamics of peripheral globules in melanocytic lesions predict melanoma risk more accurately than static features alone, informing tailored surveillance strategies.
Enfortumab vedotin (EV) therapy in advanced urothelial carcinoma is frequently associated with cutaneous adverse events (cAEs). These EV-induced skin toxicities correlate independently with improved progression-free and overall survival, ev
A multicenter prospective real-world study in China evaluated treatment outcomes of tinea capitis, highlighting itraconazole’s superior efficacy over terbinafine for certain fungal strains like Microsporum canis, informing optimized a
Early results from the RESET-PV trial indicate that CD19 CAR T-cell therapy without lymphodepleting preconditioning is feasible and safe for pemphigus vulgaris, offering significant clinical improvement and durable B-cell depletion.
Oral nicotinamide reduces keratinocyte carcinoma incidence in high-risk individuals, providing significant cost savings and quality-adjusted life-year gains, supporting its role as a cost-effective preventive strategy.
Reflectance confocal microscopy (RCM) combined with dermoscopy significantly improves detection and management of equivocal pigmented macules on the head and neck, reducing missed malignancies and overtreatment in a study of 2006 lesions.
